FDA inspection
Aurolife Pharma, LLC: FDA inspection ending Feb 12, 2020
FDA inspection 1118285 · Dayton, NJ
Key facts
| Inspection ID | 1118285 |
|---|---|
| Firm | Aurolife Pharma, LLC |
| FEI number | 3005796917 |
| Address | 2400 US Highway 130 |
| City | Dayton |
| State | NJ |
| ZIP | 08810-1519 |
| Fiscal year | 2020 |
| Inspection end date | Feb 12, 2020 |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
| Warning letter | 607087 |
At a glance
- None Citations
- 1–9 Posted citations
- Yes Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data